Australia Biopharmaceutical Excipients Market Size & Outlook
Australia biopharmaceutical excipients market, 2018-2030 (US$M)
Related Markets
Australia biopharmaceutical excipients market highlights
- The Australia biopharmaceutical excipients market generated a revenue of USD 55.1 million in 2023 and is expected to reach USD 83.3 million by 2030.
- The Australia market is expected to grow at a CAGR of 6.1% from 2024 to 2030.
- In terms of segment, carbohydrates was the largest revenue generating product in 2023.
- Polyols is the most lucrative product segment registering the fastest growth during the forecast period.
Biopharmaceutical excipients market data book summary
| Market revenue in 2023 | USD 55.1 million |
| Market revenue in 2030 | USD 83.3 million |
| Growth rate | 6.1% (CAGR from 2023 to 2030) |
| Largest segment | Carbohydrates |
| Fastest growing segment | Polyols |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Specialty Excipients/Others, Solubilizes & Surfactants/Emulsifiers, Polyols, Carbohydrates |
| Key market players worldwide | Merck KGaA, Basf SE, Associated British Foods PLC, IMCD NV, Clariant AG, Evonik Industries AG, Colorcon, Sigachi, Spectrum Chemical Manufacturingrp, Roquette America, DFE Pharma, J. Rettenmaier & Söhne |
Other key industry trends
- In terms of revenue, Australia accounted for 2.1% of the global biopharmaceutical excipients market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China biopharmaceutical excipients market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 355.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biopharmaceutical Excipients Market Scope
Biopharmaceutical Excipients Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia biopharmaceutical excipients market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical excipients market will help companies and investors design strategic landscapes.
Carbohydrates was the largest segment with a revenue share of 35.93% in 2023. Horizon Databook has segmented the Australia biopharmaceutical excipients market based on specialty excipients/others, solubilizes & surfactants/emulsifiers, polyols, carbohydrates covering the revenue growth of each sub-segment from 2018 to 2030.
The key companies offering biopharma excipients in Australia include Croda International Plc and SPI Pharma. These operate through subsidiaries in the country. For example, Anzchem is a wholly owned subsidiary of SPI Pharma located in New South Wales, Australia.
The major biopharma companies in the country include Juno Pharmaceuticals. Healthcare organizations, such as SafeBiologics, comprise diverse healthcare groups focused on the development of safe biologics & biosimilars.
Reasons to subscribe to Australia biopharmaceutical excipients market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia biopharmaceutical excipients market databook
-
Our clientele includes a mix of biopharmaceutical excipients market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia biopharmaceutical excipients market , including forecasts for subscribers. This country databook contains high-level insights into Australia biopharmaceutical excipients market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia biopharmaceutical excipients market size, by product, 2018-2030 (US$M)
Australia Biopharmaceutical Excipients Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
